Literature DB >> 11453589

Clinical characteristics and outcome of patients with invasive pneumococcal disease, Puy-de-Dôme, France, 1994-1998.

H Laurichesse1, J P Romaszko, L T Nguyen, B Souweine, V Poirier, D Guólon, M André, M Ruivard, C De Champs, D Caillaud, A Labbé, J Beytout.   

Abstract

A surveillance program for invasive pneumococcal disease was undertaken in Puyde-Dĵme, an administrative district of the region Auvergne in France, from 1 January 1994 to 31 December 1998. A total of 214 cases were identified. The annual incidence of invasive pneumococcal disease increased (P=0.04) from 5.5 in 1994 to 9.3 cases per 10(5) person-years in 1998. The highest incidences were for children <2 years of age (59.2 cases per 10(5) person-years) and for adults > or = 65 years (18 cases per 10(5) person-years). Clinical diagnoses, available in 200 patients, included acute pneumonia (62%), meningitis (10%), sepsis without focus (20%), and others (8%). The most frequent chronic medical conditions of the patients included smoking, alcoholism, cardiovascular and pulmonary diseases, and malignancies. Thirty-one percent of the isolates were nonsusceptible to penicillin. Penicillin resistance (MIC > or = 0.1 mg/l) was more frequent (P=0.02) in cancer patients. The overall case-fatality rate was 21.5%. Risk factors for death were age, sex, and underlying diseases of the patients, along with the severity of illness. These population-based findings should convince clinicians to offer pneumococcal vaccine to patients at high risk for invasive pneumococcal disease, thereby increasing vaccination coverage levels in France.

Entities:  

Mesh:

Year:  2001        PMID: 11453589     DOI: 10.1007/pl00011269

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  10 in total

1.  Initial management of and outcome in patients with pneumococcal bacteremia: a retrospective study at a Swiss university hospital, 2003-2009.

Authors:  A-M Giner; S P Kuster; R Zbinden; C Ruef; B Ledergerber; R Weber
Journal:  Infection       Date:  2011-11-08       Impact factor: 3.553

2.  African meningitis belt pneumococcal disease epidemiology indicates a need for an effective serotype 1 containing vaccine, including for older children and adults.

Authors:  Bradford D Gessner; Judith E Mueller; Seydou Yaro
Journal:  BMC Infect Dis       Date:  2010-02-10       Impact factor: 3.090

3.  Burden of paediatric invasive pneumococcal disease in Europe, 2005.

Authors:  E D G McIntosh; B Fritzell; M A Fletcher
Journal:  Epidemiol Infect       Date:  2006-09-07       Impact factor: 2.451

4.  Streptococcus pneumoniae skin and soft tissue infections: characterization of causative strains and clinical illness.

Authors:  J M Garcia-Lechuz; O Cuevas; C Castellares; C Perez-Fernandez; E Cercenado; E Bouza
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-03-20       Impact factor: 5.103

5.  Time to positivity in blood cultures of adults with Streptococcus pneumoniae bacteremia.

Authors:  Galo Peralta; María José Rodríguez-Lera; Jose Carlos Garrido; Luis Ansorena; María Pía Roiz
Journal:  BMC Infect Dis       Date:  2006-04-27       Impact factor: 3.090

Review 6.  Controlling invasive pneumococcal disease: is vaccination of at-risk groups sufficient?

Authors:  M A Fletcher; D S Laufer; E D G McIntosh; C Cimino; F J Malinoski
Journal:  Int J Clin Pract       Date:  2006-04       Impact factor: 2.503

7.  Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia.

Authors:  Jaime E Ordóñez; John J Orozco
Journal:  BMC Infect Dis       Date:  2014-03-28       Impact factor: 3.090

8.  Clinical and economic burden of invasive pneumococcal disease in adults: a multicenter hospital-based study.

Authors:  Joon Young Song; Jun Yong Choi; Jin Soo Lee; In-Gyu Bae; Young Keun Kim; Jang Wook Sohn; Yu Mi Jo; Won Suk Choi; Jacob Lee; Kyung Hwa Park; Woo Joo Kim; Hee Jin Cheong
Journal:  BMC Infect Dis       Date:  2013-05-04       Impact factor: 3.090

Review 9.  Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance.

Authors:  Joon Young Song; Moon H Nahm; M Allen Moseley
Journal:  J Korean Med Sci       Date:  2013-01-08       Impact factor: 2.153

10.  Impact of Asthma on the Severity of Serious Pneumococcal Disease.

Authors:  Ravneet K Dhillon; Barbara P Yawn; Kwang Ha Yoo; Thomas G Boyce; Robert M Jacobson; Michaela E McGree; Amy L Weaver; Young J Juhn
Journal:  Epidemiology (Sunnyvale)       Date:  2011-12-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.